Research Reports | Market Assessment
November 2017

Narcolepsy | Treatment Algorithms | Claims Data Analysis | US

A number of therapies from a range of drug classes are available to address the symptoms of narcolepsy including excessive daytime sleepiness and cataplexy.  Our Treatment Algorithms research leverages national patient-level claims data to explore the use of key therapies in narcolepsy, such as modafinil, armodafinil, and Xyrem, in both newly diagnosed and recently-treated patients. These data provide important information regarding the patient journey in narcolepsy including treatment duration, switch patterns, and persistence and compliance by drug.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed narcolepsy patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed narcolepsy patients?
  • Where has Xyrem been integrated into the treatment algorithm?
  • What proportion of narcolepsy patients receive drug therapy within a year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
  • What percentage of narcolepsy patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with narcolepsy?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports